Search

Displaying results 2771 - 2780 of 4588 in total
  1. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

  2. Drug

    Sesame oil

    go.drugbank.com/drugs/DB11172
    ApprovedNutraceutical

    Sesame oil is considered an indirect additive used in food cotact substances by the FDA.

  3. Drug

    Thioproperazine

    go.drugbank.com/drugs/DB01622
    Approved

    Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually ...

  4. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    [L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials.

  5. Drug

    Clomethiazole

    go.drugbank.com/drugs/DB06470
    Investigational

    It is a drug which is structurally related to thiamine (vitamin B1) but acts like a sedative, hypnotic, muscle relaxant and anticonvulsant.

  6. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

  7. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]

  8. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states [F104].

  9. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.

  10. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]